Alzheimer's Disease Through the Symbiont Lens: Candida albicans, Amyloid as Defensive Encapsulation, and the SOX9-MEGF10-Hk1 Astrocyte Triad

This paper is an extension of Candida Albicans as a Biochemical computer framework. The science contained stands on its own, but it is yet another foundation support beam for the Redacted Science framework Abstract Anti-amyloid antibody therapy for Alzheimer's disease has produced reliable biomarker engagement (PET-detectable amyloid clearance) without functional benefit. Across more than seventeen trials encompassing over twenty thousand participants, the absolute cognitive effects have been characterized as absent or trivial, with no measurable benefit in women or in APOE4 carriers (60 to 75 percent of patients). In parallel with this twelve-year program, a separate published literature has accumulated documenting fungal presence in one hundred percent of Alzheimer's brain samples examined in the reported Pisa/Carrasco cohorts (across multiple brain regions, with controls negative), antimicrobial peptide function of amyloid β against Candida albicans and other pathogens, causal demonstration of fungal-induced amyloid deposition in mouse and human iPSC-organoid models, and convergent return of antifungal compounds as top-ranked hits from blind drug screens against amyloid β aggregation across two independent screening methodologies. This paper integrates the published record into a coherent disease architecture. Alzheimer's disease is reframed as the brain-stage manifestation of chronic Candida albicans dysregulation, with amyloid plaques functioning as antimicrobial defensive encapsulation around live fungal targets. The chronic inflammatory state spans three coexisting cellular compartments: exhausted and inflammatory-locked astrocyte subpopulations (Bell et al. 2025; Chen et al. 2025) and clonal-hematopoiesis-driven microglia-like cells of bone-marrow origin infiltrating through compromised blood-brain barrier (Huang et al. 2026). The host's astrocytic SOX9-MEGF10 phagocytic clearance machinery is predicted to fail through autoantibody-mediated functional decoupling: the anti-SOX9/SOX10 autoantibody mechanism is documented in chronic-Candida APECED patients (Hedstrand et al. 2001), and the framework predicts its operation in the relevant AD subgroup. APOE4 carriers are reframed as a host-symbiont architecture variant with antimicrobial properties calibrated for pathogen-rich environments, supported by cross-cultural cognitive evidence (Oriá et al. 2010; Trumble et al. 2017; Zhao et al. 2020; Lathika Rajendrakumar et al. 2025); the lecanemab APOE4 failure is mechanistically resolved as architecture-specific encapsulation removal in patients whose architecture depends on the encapsulation. The reframe accounts for anti-amyloid antibody trial failures, the ARIA adverse event class as encapsulation-stripping signature, and the differential failure across patient subpopulations. The therapeutic prediction is that antifungal therapy targeting Candida albicans in early-stage Alzheimer's disease with documented fungal burden will produce cognitive benefit substantially exceeding approved anti-amyloid antibodies. A multi-arm adaptive platform trial design is specified, with pre-specified APOE4 stratification predicting larger benefit in APOE4 carriers than APOE3/3 patients. Ten testable predictions are assembled, including a structurally symmetric differential failure prediction for emerging siSOX9 nanoparticle therapies stratified by anti-SOX9 IgG status. The integration positions Alzheimer's disease within the Redacted Science Research Initiative's stuck-state framework as the terminal manifestation of the lifetime symbiont dysregulation visible in earlier-life conditions, including type 2 diabetes, irritable bowel syndrome, and Parkinson's disease, with the pituitary engagement architecture connecting the brain-stage manifestation to the broader corpus.